NEW YORK (GenomeWeb News) – Vermillion has signed a cooperative research and development agreement, or CRADA, with the US Army Medical Research and Materiel Command for the evaluation of the OVA1 ovarian cancer diagnostic test, Vermillion announced today.

The project, which follows a decision by the Army to cover the OVA1 test in January 2012, will be carried out in two phases to assess the cost-benefit profile of Vermillion's test as a presurgical standard of care in women with pelvic masses and to evaluate OVA1's clinical utility in a managed care setting.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.